{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"}],"units":"Participants"}],"groups":[{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Schedule A: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.045 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Schedule A: IMGN632 0.045 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.09 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"Schedule A: IMGN632 0.09 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.18 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Schedule A: IMGN632 0.18 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.3 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Schedule A: IMGN632 0.3 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.45 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Schedule A: IMGN632 0.45 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG006","title":"Schedule B: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.03 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG007","title":"Schedule B: IMGN632 0.03 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.06 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG008","title":"Schedule B: IMGN632 0.06 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety population included all participants who received at least 1 dose of study drug. ADA data were collected and reported per treatment schedule and dose in both phases (dose escalation and expansion) combined. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Number of Participants With Anti-drug Antibodies (ADAs) at Any Post-baseline Visit","type":"SECONDARY","unitOfMeasure":"Participants"}